Vizimpro

Chemical Namedacomitinib
Dosage FormTablet (oral; 15 mg, 30 mg, 45 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyPfizer Inc.
Approval Year2018

Indication

  • To treat of metastatic non-small cell lung cancer in cases with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations preceeding the use of other therapies.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vizimpro (Dacomitinib) Prescribing Information2018Pfizer Inc., New York, NY